OrbiMed Raises $3.5 Billion Across Private Investment Funds
NEW YORK, March 1, 2021-- OrbiMed, a leading life sciences investment firm, announced $3.5 billion in commitments for its latest private investment funds, including $1.5 billion for OrbiMed Private Investments VIII, $800 million for OrbiMed Asia Partners IV, and $1.2 billion for OrbiMed Royalty & Credit Opportunities III. Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds and sovereign wealth funds.
• OrbiMed Private Investments VIII invests primarily in venture capital stage opportunities in North America and Europe, with a focus on biotechnology, medical device, and diagnostics companies. This fund targets investments from $10 million to $100 million across approximately 40 portfolio companies.
• OrbiMed Asia Partners IV invests primarily in China and India, from venture capital through growth stage across biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services. This fund targets investments from $10 million to $100 million in approximately 20 portfolio companies.
• OrbiMed Royalty & Credit Opportunities III invests globally through providing structured credit and royalty monetization financing solutions for healthcare companies and institutions. This fund generally invests from $10 million to $150 million per opportunity.
Where appropriate, OrbiMed invests across multiple funds, bringing potential investment amounts to upwards of $250 million per portfolio company. These new funds bring OrbiMed’s assets under management to approximately $18 billion across public equity, private equity and credit/royalty strategies. These extensive financial resources allow OrbiMed to partner with healthcare companies across their life cycle, solving financing needs from start-up seed capital through to growth equity and non-dilutive debt capital.
OrbiMed is led by its nineteen partners, with a growing team of more than 100 professionals contributing diverse, complementary skills across finance, strategy, and new company formation. OrbiMed combines its substantial financial resources with extensive global team capabilities to partner with exceptional management teams in building the next generation of world-class healthcare companies.
OrbiMed is a leading healthcare investment firm, with approximately $18 billion in assets under management. OrbiMed invests globally across the healthcare industry through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya and other key global markets.
Carter Neild, CFA
Phone: (212) 739.6469
Venture Capital Database